Morgan Stanley Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price

Eli Lilly and Company (NYSE:LLY) had its price target upped by Morgan Stanley from $1,090.00 to $1,171.00 in a report issued on Thursday,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

Several other equities research analysts have also recently weighed in on the company. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday. UBS Group lifted their price objective on Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a report on Friday, November 7th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and raised their target price for the company from $886.00 to $1,104.00 in a research report on Monday. Finally, Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $999.32.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,022.00 on Thursday. The company has a market capitalization of $966.19 billion, a P/E ratio of 66.80, a P/E/G ratio of 1.21 and a beta of 0.43. The company’s 50-day simple moving average is $820.93 and its two-hundred day simple moving average is $779.85. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,032.95. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the previous year, the firm posted $1.18 earnings per share. The company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Institutional Trading of Eli Lilly and Company

Hedge funds and other institutional investors have recently made changes to their positions in the business. Regal Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company by 10.0% during the third quarter. Regal Investment Advisors LLC now owns 2,750 shares of the company’s stock worth $2,098,000 after purchasing an additional 249 shares during the last quarter. Brown Brothers Harriman & Co. grew its position in Eli Lilly and Company by 0.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 181,851 shares of the company’s stock worth $138,752,000 after purchasing an additional 787 shares during the period. Benchmark Investment Advisors LLC purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $377,000. Cadence Bank lifted its holdings in shares of Eli Lilly and Company by 0.4% in the 3rd quarter. Cadence Bank now owns 11,391 shares of the company’s stock valued at $8,692,000 after buying an additional 48 shares during the period. Finally, EHP Funds Inc. purchased a new stake in shares of Eli Lilly and Company in the third quarter worth about $666,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.